Novavax

CEPI undertakes to provide Novavax up to $ 388 million for the development and manufacture of Coronavirus vaccine candidate NVX-COV2373 against SARS-COV-2.

Commercial license agreement between Novavax and the Serum Institute of India (SII) on the use of the proprietary Matrix-M ™-vaccine adjuvan from Novavax at the malaria vaccine candidate from the Serum Institute of India.

In 2009, Novavax CPL Biologicals Ltd., a joint venture with Cadila Pharmaceutical Ltd., founded a number of VLP vaccine candidates from Novavax and certain therapeutic candidates for Cadila for India.

Novavax has received an order to produce NVX-COV2373, the COVID-19 vaccine candidate from Novavax, from the US Department of Defense (DOD). JPEO-CRBND-AB has agreed to provide up to $ 60 million in the United States by financing the Defense Health Program to support Novavax in the production of several components of the vaccine. The agreement includes the delivery of 10 million doses NVX-COV2373 for DOD in 2020, which could be used in clinical studies in phase 2/3 or as part of an emergency permit (EUA) if it is approved by the US FDA.